Revenue qualityDanger
매출 흑자인데 영업CF 적자 (OCF/매출 -20%). 통계적 정황 신호이며 회계부정 단정이 아닙니다.
$5.67+2.53%
2026-10-09 closeEntrada Therapeutics's published financial data is dated 2026-10-04. 2024 revenue was $211M. 2024 operating profit was $47M.
Reported results
Financial safety
Reference indicatorAs of 2024Safe zoneFinancial-metric reference signal
Altman Z'' zoneZ'' 9.40
Distress
Grey
Safe
- Altman Z''
- 9.40
- Beneish M-Score
- -1.39
- Sloan accrual
- 20.36%
Statistical manipulation-risk signal
부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.
Factual information, not investment advice.
Earnings quality · Piotroski F-Score
6/9Moderate
Piotroski measures year-over-year financial improvement, not absolute quality.
Financial improvement score6/9
Profitability
- Positive ROAPass
- Positive OCFNot passed
- Improving ΔROAPass
- Accruals (OCF > net income)Not passed
Leverage & liquidity
- Lower debtPass
- Higher current ratioPass
- No new sharesPass
Efficiency
- Higher gross marginNot passed
- Higher asset turnoverPass
Calculation note: F7(신주)은 equity/asset 유지로 근사
Already-stable companies may score lower when year-over-year improvement is limited.
Factual information, not investment advice.
Forensic signals
Anomaly and structural signals observed in the financial statements.
Margin trendWarning
영업외손익 급변 (영업이익 대비 47% 규모 변동) — 일회성 손익 주의. 통계적 정황 신호이며 회계부정 단정이 아닙니다.
Factual information, not investment advice.
Risk sensitivity — adverse assumptions
Metric changes under stated assumptions; not a forecast or investment advice.
Base metrics
- Operating margin
- 22.3%
- Interest coverage
- 2.5x
- Return on equity (ROE)
- 15.3%
Operating margin −5pp
TolerableInterest coverageBase 2.5x adverse case 2x
Return on equity (ROE)Base 15.3% adverse case 4.2%
Revenue −15%
TolerableInterest coverageBase 2.5x adverse case 2.1x
Return on equity (ROE)Base 15.3% adverse case 5%
Interest rate +2pp
TolerableInterest coverageBase 2.5x adverse case 2.3x
Return on equity (ROE)Base 15.3% adverse case 6.2%
Interest coverage limit
Current margin 13.5ppInterest coverage limit at an operating margin of 8.8%
Interest expense coverage threshold
Quantus Signal · live data · not investment advice · Privacy Policy